bridgebio to present outcomes data through 42 months from the open-label extension of attribute-cm, the phase 3 study of acoramidis for treatment of attr-cm, at 2024 aha scientific sessions

PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM. Featured Science Oral Presentation: Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes from the ATTRibute-CM Open-Label Extension (OLE) Study Session Title: Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations Presenter: Daniel Judge, M.D. of Medical University of South Carolina Date: Monday, November 18 at 9:45 am CT/10:45 am ET Moderated Digital Posters: Costs and Healthcare Resource Utilization in Transthyretin Amyloid Cardiomyopathy Exceeds That of Generalized Heart Failure Session Title: Socioeconomic Insights and Innovations in Heart Failure Presenter: Justin Grodin, M.D. of UT Southwestern Medical Center Date: Sunday, November 17 at 10:00 am CT/11:00 am ET Evolving Baseline Risk in Patients with Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials Session Title: Cardiac Amyloidosis 2024: Advances in Prognostication and Management Presenter: Ahmad Masri, M.D. of Oregon Health & Science University Date: Sunday, November 17 at 11:10 am CT/12:10 pm ET Acoramidis Improved Survival in Patients with Transthyretin Cardiac Amyloidosis Regardless of Prior Cardiovascular Hospitalization Session Title: Cardiac Amyloidosis 2024: Advances in Prognostication and Management Presenter: Kevin Alexander, M.D. of Stanford University School of Medicine Date: Sunday, November 17 at 11:20 am CT/12:20 pm ET The presentation and posters will be available following the sessions on the Presentations page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. About BridgeBio Pharma, Inc. BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook. BridgeBio Contact: Vikram Bali [email protected] (650)-789-8220 View All News Stay Informed. COMPANY About Us opens in new window Careers opens in new window Investors opens in new window Legal Policies opens in new window INSIGHTS On Rare Podcast ↗ opens in new window News opens in new window SCIENCE Clinical Trial Info opens in new window Presentations & Publications opens in new window Grants & Funding opens in new window MEDICINES & PIPELINE Pipeline opens in new window Attruby® (acoramidis) ↗ opens in new window NULIBRY® (fosdenopterin) ↗ opens in new window PATIENTS Stories opens in new window Access opens in new window Support opens in new window SOCIAL LinkedIn ↗ opens in new window X ↗ opens in new window Facebook ↗ opens in new window Instagram ↗ opens in new window Youtube ↗ opens in new window Tiktok ↗ opens in new window This site is intended for U.S. residents. BridgeBio, Attruby, the Attruby logo, ForgingBridges, and the ForgingBridges logo are trademarks of BridgeBio Pharma, Inc. All other trademarks are property of their respective owners. © 2026 BridgeBio Pharma Inc. - All rights reserved Powered By Q4 Inc. 5.187.1.9 (opens in new window)

The release as fetched from its publisher. bridgebio.com ↗